107PPhase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results

Background: In patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC), TAS-102 -a combination of trifluridine and tipiracil- plus bevacizumab (bev) combination therapy has shown a promising activity with manageable safety. In previously reported this combination therapy, TAS-102 have been given every 4 weeks (35mg/m² given orally twice daily on day 1-5 and 8-12 in a 28-day cycle) and bev have been administered every 2 weeks. The aim of this study was to assess the activity and safety of biweekly TAS-102 (given orally twice daily on day 1-5 every 2 weeks) with bev combination for pts with mCRC.

https://ift.tt/2Rkrz6s